IsoTis takes bone graft to US dental market:
This article was originally published in Clinica
IsoTis OrthoBiologics has received US FDA 510(k) clearance to use its advanced synthetic bone graft material, OsSatura BCP, in dental applications. The company, which already markets in the US demineralised bone matrix (DBM) product range, said that the dental field represented a strong area of growth for IsoTis. The dental arena accounts for around 10% of the Lausanne, Switzerland firm's sales. The new dental product is composed of approximately 80% hydroxyapatite and 20% ss-tricalcium phosphate.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.